BRAF and skin cancer: In the 5‐year follow‐up analysis of the COmbined LGX818 (encorafenib) used with MEK162 (binimetinib) in BRAF mutant Unresectable Skin cancer (COLUMBUS) trial,17 LVD events were noted mostly in the first 6 months (5.1%) compared to 6–12 month (3.4%), 12–18 month (3.4%) and 18–24 month period (1.7%).